How to reduce clinical trial site investigator turnover

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/drvarayu)
(Image: Getty/drvarayu)
CTTI has released new recommendations that can be implemented by sponsors, CROs, and others, in order to decrease the number of ‘one and done’ clinical trial site investigators.

The Clinical Trials Transformation Initiative (CTTI) released the recommendations at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit, which took place last week in Florida.

CTTI was co-founded by Duke University and the US Food and Drug Administration (FDA).

The new recommendations focus on four areas:

  1. Developing site-based research infrastructure and staff
  2. Optimizing trial execution and conduct
  3. Improving site budget and contract negotiations
  4. Discovering additional trials to conduct

Gerrit Hamre, project manager at CTTI said the evidence-based solutions can be implemented across the clinical trial enterprise, including sponsors, contract research organizations (CROs), as well as the site investigators.

By creating a supportive clinical research ecosystem—one that provides adequate infrastructure and staff, continuous training, clear operational and financial procedures, and a climate of mutual respect—investigators will feel more engaged and empowered to continue working in the clinical research space​,” he told Outsourcing-Pharma.com.

A balancing act

Many investigators leave clinical research due to a difficulty balancing workload, time requirements to conduct trials, data and safety reporting burdens, and financial issues, Hamre explained.

However, the professional and personal rewards of conducting research are also evident, and the ability to overcome challenges associated with clinical research is clearly articulated​,” he added.

The goal of the new recommendations is to provide “a roadmap to address these challenges and, ultimately, decrease the number of ‘one and done’ investigators​,” said Hamre.

The project was funded in part by the US FDA grant.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers